XML 40 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versu s Performance The following tables provide pay versus performance information required by Regulation S-K. For information regarding the Company’s pay-for-performance philosophy and how the Company aligns executive compensation with the Company’s performance, refer to “Executive Compensation: Compensation Discussion and Analysis.”
Year |  | Summary Compensation Table (“SCT”) Total for First PEO(1) |  | SCT Total for Second PEO(1) |  | SCT Total for Third PEO(1) |  | Compensation Actually Paid (“CAP”) to First PEO(2) |  | CAP to Second PEO |  | CAP to Third PEO |  | Average SCT Total for Non-PEO NEOs(3) |  | Average CAP to Non-PEO NEOs(2)(3)
2024 |  |  | $ | 3,301,012 |  |  |  |  | N/A |  |  |  |  | N/A |  |  |  |  | $ | 4,424,038 |  |  |  |  | N/A |  |  |  |  | N/A |  |  |  |  | $ | 2,078,530 |  |  |  |  | $ | 2,611,401 |  |
2023 |  |  | $ | 2,237,839 |  |  |  |  | N/A |  |  |  |  | N/A |  |  |  |  | $ | 1,620,732 |  |  |  |  | N/A |  |  |  |  | N/A |  |  |  |  | $ | 1,721,885 |  |  |  |  | $ | 1,191,132 |  |
2022 |  |  | N/A |  |  |  |  | $ | 4,655,746 |  |  |  |  | N/A |  |  |  |  | N/A |  |  |  |  | $ | 540,703 |  |  |  |  | N/A |  |  |  |  | $ | 1,699,411 |  |  |  |  | $ | 364,560 |  |
2021 |  |  | N/A |  |  |  |  | $ | 6,848,969 |  |  |  |  | N/A |  |  |  |  | N/A |  |  |  |  | $ | 9,015,601 |  |  |  |  | N/A |  |  |  |  | $ | 2,107,197 |  |  |  |  | $ | 2,525,213 |  |
2020 |  |  | N/A |  |  |  |  | $ | 6,438,682 |  |  |  |  | $ | 7,597,254 |  |  |  |  | N/A |  |  |  |  | $ | 6,438,682 |  |  |  |  | $ | 4,870,493 |  |  |  |  | $ | 3,196,697 |  |  |  |  | $ | 2,468,265 |  |
|  |  | Value of Initial Fixed $100 Investment Based On: |  |  |  |  |  |  |  |  |  |  |  |
Year |  | Total Shareholder Return |  | Peer Group Total Shareholder Return(4) |  | Net (Loss) Income ($ in thousands) |  | Adjusted EBITDA ($ in thousands)(5)
2024 |  |  | $ | 47.21 |  |  |  |  | $ | 102.90 |  |  |  |  | $ | (99,069 | ) |  |  |  | $ | 224,022 |  |
2023 |  |  | $ | 33.47 |  |  |  |  | $ | 99.53 |  |  |  |  | $ | (60,408 | ) |  |  |  | $ | 200,418 |  |
2022 |  |  | $ | 53.47 |  |  |  |  | $ | 102.25 |  |  |  |  | $ | 66,331 |  |  |  |  | $ | 241,033 |  |
2021 |  |  | $ | 97.91 |  |  |  |  | $ | 138.98 |  |  |  |  | $ | 130,937 |  |  |  |  | $ | 265,476 |  |
2020 |  |  | $ | 88.31 |  |  |  |  | $ | 131.41 |  |  |  |  | $ | (796,488 | ) |  |  |  | $ | 219,872 |  |
(1) Dr. Swift served as our principal executive officer ("PEO") for the entirety of 2024 and 2023. Mr. Ordan served as our PEO for the entirety of 2021 and 2022. Mr. Ordan and Dr. Medel served as our PEOs in 2020. For purposes of the table, Dr. Swift is our First PEO, Mr. Ordan is our Second PEO and Dr. Medel is our Third PEO. (2) Compensation “actually paid” is calculated in accordance with Item 402(v) of Regulation S-K, however, as required, the dollar amounts include (among other items) equity compensation that may be realizable in future periods, and as such, the dollar amounts shown do not fully represent the actual final amount of compensation earned or actually paid during the applicable years. The table below sets forth each adjustment made during the years presented in the table to calculate the compensation “actually paid,” in accordance with Item 402(v) of Regulation S-K, to our NEOs during each year in the table. (3) During 2024, our non-PEO NEOs consisted of Ms. Rossi, Ms. Moore, Mr. Richards, Dr. Pickert and Mr. Wood. In 2023, our non-PEO NEOs consisted of Ms. Moore, Mr. Richards, Dr. Pickert and Mr. Wood. In 2022, our non-PEO NEOs consisted of Mr. Richards and Dominic Andreano, our former Executive Vice President and General Counsel, Ms. Moore and Dr. Swift. During 2021, our non-PEO NEOs consisted of Mr. Richards and Andreano, Mr. John C. Pepia, Ms. Moore and Roger “Mack” Hinson, M.D. During 2020, our non-PEO NEOs consisted of Mr. Richards, Andreano and Pepia, Dr. Hinson, Mr. Stephen D. Farber and Mr. Nicholas J. Nikolopoulos. (4) The peer group used by the Company consists of the companies used in the S&P 600 Health Care Index, the index used in the Company’s performance graph reported in Part II, Item 5 of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. (5) Adjusted EBITDA is the financial measure from the Tabular List of 2024 Most Important Measures shown below, which, in the Company’s assessment, represents for 2024 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 32 and is a non-GAAP financial measure.
Adjustments to Calculate Compensation “Actually Paid” to First PEO(7) |  | 2024 | 2023
SCT Total |  |  | $ | 3,301,012 |  |  |  | $ | 2,237,839 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(8) |  |  | $ | (1,180,087 | ) |  |  | $ | (1,025,015 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(9) |  |  | $ | 2,303,113 |  |  |  | $ | 407,908 |  |
CAP Total |  |  | $ | 4,424,038 |  |  |  | $ | 1,620,732 |  |
Adjustments to Calculate Compensation “Actually Paid” to Second PEO(7) |  | 2022 |  | 2021 |  | 2020
SCT Total |  |  | $ | 4,655,746 |  |  |  |  | $ | 6,848,969 |  |  |  |  | $ | 6,438,682 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(8) |  |  | $ | (3,500,013 | ) |  |  |  | $ | (3,500,021 | ) |  |  |  | $ | (4,999,998 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(9) |  |  | $ | (615,030 | ) |  |  |  | $ | 5,666,653 |  |  |  |  | $ | 4,999,998 |  |
CAP Total |  |  | $ | 540,703 |  |  |  |  | $ | 9,015,601 |  |  |  |  | $ | 6,438,682 |  |
Adjustments to Calculate Compensation “Actually Paid” to Third PEO(7) |  | 2020
SCT Total |  |  | $ | 7,597,254 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(8) |  |  | $ | (6,150,001 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(9) |  |  | $ | 3,423,240 |  |
CAP Total |  |  | $ | 4,870,493 |  |
Adjustments to Calculate Compensation “Actually Paid” to |  | 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Non-PEO NEOs(6) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SCT Total |  |  | $ | 2,078,530 |  |  |  |  | $ | 1,721,885 |  |  |  |  | $ | 1,699,411 |  |  |  |  | $ | 2,107,197 |  |  |  |  | $ | 3,196,697 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(7) |  |  | $ | (715,395 | ) |  |  |  | $ | (931,681 | ) |  |  |  | $ | (1,081,261 | ) |  |  |  | $ | (990,016 | ) |  |  |  | $ | (2,163,436 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(8) |  |  | $ | 1,248,266 |  |  |  |  | $ | 400,928 |  |  |  |  | $ | (253,590 | ) |  |  |  | $ | 1,408,032 |  |  |  |  | $ | 1,435,004 |  |
CAP Total |  |  | $ | 2,611,401 |  |  |  |  | $ | 1,191,132 |  |  |  |  | $ | 364,560 |  |  |  |  | $ | 2,525,213 |  |  |  |  | $ | 2,468,265 |  |
(6)As shown in these tables, the Compensation “Actually Paid” totals represent the SCT totals for the applicable year, but adjusted as required by SEC rules to include the fair value of current and prior year equity awards that are outstanding, vested or forfeited during the applicable year, instead of the grant date value of awards granted during the applicable year. (7) Represents the total of the amounts reported in the Stock Awards and Option Awards columns of the SCT for the applicable year. (8) The fair value of equity component of the CAP calculation was determined in accordance with SEC methodology for this disclosure. Unlike the SCT, which reflects the grant date fair value of equity awards granted during the applicable year, the CAP table reflects equity fair value as follows: • for awards granted during the applicable year (and which are still outstanding), the year-end value; plus • for awards granted during prior years that were still outstanding as of the applicable year-end, the change in value as of the applicable year-end compared against the prior year-end; plus • for awards granted in prior years that vested during the applicable year, the change in value as of the vesting date compared against the prior year-end; plus • for any awards granted in the applicable year that vested during the applicable year, the value as of the vesting date; plus • the value of any dividend equivalents that were paid during the applicable year that are not otherwise included in total compensation; minus • for awards granted in prior years that were forfeited during the applicable year, the value as of the prior year-end. The specific calculations with respect to the CAP fair value of equity for the relevant years are shown in the tables below:
First PEO – CAP Equity Adjustments |  | 2024 | 2023
YE Value of Current Year Awards Outstanding as of YE |  |  | $ | 2,057,295 |  |  |  | $ | 616,999 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  |  | $ | 240,247 |  |  |  | $ | (187,294 | ) |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  |  | $ | 5,571 |  |  |  | $ | (21,797 | ) |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  |  | $ | — |  |  |  | $ | — |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  |  | $ | — |  |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  |  | $ | — |  |  |  | $ | — |  |
Value of Equity for CAP Purposes |  |  | $ | 2,303,113 |  |  |  | $ | 407,908 |  |
Second PEO – CAP Equity Adjustments |  | 2022 |  | 2021 |  | 2020
YE Value of Current Year Awards Outstanding as of YE |  |  | $ | — |  |  |  |  | $ | 4,664,583 |  |  |  |  | $ | 3,000,006 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | — |  |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  |  | $ | (1,748,149 | ) |  |  |  | $ | 1,002,070 |  |  |  |  | $ | — |  |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  |  | $ | 1,133,119 |  |  |  |  | $ | — |  |  |  |  | $ | 1,999,992 |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | — |  |
Value of Equity for CAP Purposes |  |  | $ | (615,030 | ) |  |  |  | $ | 5,666,653 |  |  |  |  | $ | 4,999,998 |  |
Third PEO – CAP Equity Adjustments |  | 2020
YE Value of Current Year Awards Outstanding as of YE |  |  | $ | 5,583,464 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  |  | $ | (546,293 | ) |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  |  | $ | (1,613,931 | ) |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  |  | $ | — |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  |  | $ | — |  |
Value of Equity for CAP Purposes |  |  | $ | 3,423,240 |  |
Non-PEO NEOs – CAP Equity Adjustments | 2024 | 2023 | 2022 | 2021 | 2020
YE Value of Current Year Awards Outstanding as of YE |  | $ | 834,923 |  |  |  | $ | 560,818 |  |  |  | $ | 350,057 |  |  |  | $ | 1,310,553 |  |  |  | $ | 717,561 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  | $ | 122,479 |  |  |  | $ | (150,476 | ) |  |  | $ | (496,890 | ) |  |  | $ | 60,423 |  |  |  | $ | (37,398 | ) |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  | $ | 2,366 |  |  |  | $ | (9,414 | ) |  |  | $ | (106,757 | ) |  |  | $ | 37,056 |  |  |  | $ | (499,755 | ) |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  | $ | 288,498 |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | 1,254,596 |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |
Value of Equity for CAP Purposes |  | $ | 1,248,266 |  |  |  | $ | 400,928 |  |  |  | $ | (253,590 | ) |  |  | $ | 1,408,032 |  |  |  | $ | 1,435,004 |  |
Company Selected Measure Name | Adjusted EBITDA |  |  |  |
Named Executive Officers, Footnote | (1) Dr. Swift served as our principal executive officer ("PEO") for the entirety of 2024 and 2023. Mr. Ordan served as our PEO for the entirety of 2021 and 2022. Mr. Ordan and Dr. Medel served as our PEOs in 2020. For purposes of the table, Dr. Swift is our First PEO, Mr. Ordan is our Second PEO and Dr. Medel is our Third PEO. (3) During 2024, our non-PEO NEOs consisted of Ms. Rossi, Ms. Moore, Mr. Richards, Dr. Pickert and Mr. Wood. In 2023, our non-PEO NEOs consisted of Ms. Moore, Mr. Richards, Dr. Pickert and Mr. Wood. In 2022, our non-PEO NEOs consisted of Mr. Richards and Dominic Andreano, our former Executive Vice President and General Counsel, Ms. Moore and Dr. Swift. During 2021, our non-PEO NEOs consisted of Mr. Richards and Andreano, Mr. John C. Pepia, Ms. Moore and Roger “Mack” Hinson, M.D. During 2020, our non-PEO NEOs consisted of Mr. Richards, Andreano and Pepia, Dr. Hinson, Mr. Stephen D. Farber and Mr. Nicholas J. Nikolopoulos. |  |  |  |
Peer Group Issuers, Footnote | (4) The peer group used by the Company consists of the companies used in the S&P 600 Health Care Index, the index used in the Company’s performance graph reported in Part II, Item 5 of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |  |  |  |
Adjustment To PEO Compensation, Footnote | (5) Adjusted EBITDA is the financial measure from the Tabular List of 2024 Most Important Measures shown below, which, in the Company’s assessment, represents for 2024 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 32 and is a non-GAAP financial measure.
Adjustments to Calculate Compensation “Actually Paid” to First PEO(7) |  | 2024 | 2023
SCT Total |  |  | $ | 3,301,012 |  |  |  | $ | 2,237,839 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(8) |  |  | $ | (1,180,087 | ) |  |  | $ | (1,025,015 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(9) |  |  | $ | 2,303,113 |  |  |  | $ | 407,908 |  |
CAP Total |  |  | $ | 4,424,038 |  |  |  | $ | 1,620,732 |  |
Adjustments to Calculate Compensation “Actually Paid” to Second PEO(7) |  | 2022 |  | 2021 |  | 2020
SCT Total |  |  | $ | 4,655,746 |  |  |  |  | $ | 6,848,969 |  |  |  |  | $ | 6,438,682 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(8) |  |  | $ | (3,500,013 | ) |  |  |  | $ | (3,500,021 | ) |  |  |  | $ | (4,999,998 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(9) |  |  | $ | (615,030 | ) |  |  |  | $ | 5,666,653 |  |  |  |  | $ | 4,999,998 |  |
CAP Total |  |  | $ | 540,703 |  |  |  |  | $ | 9,015,601 |  |  |  |  | $ | 6,438,682 |  |
Adjustments to Calculate Compensation “Actually Paid” to Third PEO(7) |  | 2020
SCT Total |  |  | $ | 7,597,254 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(8) |  |  | $ | (6,150,001 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(9) |  |  | $ | 3,423,240 |  |
CAP Total |  |  | $ | 4,870,493 |  |
Non-PEO NEO Average Total Compensation Amount | $ 2,078,530 | $ 1,721,885 | $ 1,699,411 | $ 2,107,197 | $ 3,196,697
Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,611,401 | 1,191,132 | 364,560 | 2,525,213 | 2,468,265
Adjustment to Non-PEO NEO Compensation Footnote | (5) Adjusted EBITDA is the financial measure from the Tabular List of 2024 Most Important Measures shown below, which, in the Company’s assessment, represents for 2024 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 32 and is a non-GAAP financial measure.
Adjustments to Calculate Compensation “Actually Paid” to |  | 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Non-PEO NEOs(6) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SCT Total |  |  | $ | 2,078,530 |  |  |  |  | $ | 1,721,885 |  |  |  |  | $ | 1,699,411 |  |  |  |  | $ | 2,107,197 |  |  |  |  | $ | 3,196,697 |  |
Minus: Grant Date Fair Value of Awards Granted During the Year(7) |  |  | $ | (715,395 | ) |  |  |  | $ | (931,681 | ) |  |  |  | $ | (1,081,261 | ) |  |  |  | $ | (990,016 | ) |  |  |  | $ | (2,163,436 | ) |
Plus (Minus): CAP Adjustments Calculated Using SEC Methodology(8) |  |  | $ | 1,248,266 |  |  |  |  | $ | 400,928 |  |  |  |  | $ | (253,590 | ) |  |  |  | $ | 1,408,032 |  |  |  |  | $ | 1,435,004 |  |
CAP Total |  |  | $ | 2,611,401 |  |  |  |  | $ | 1,191,132 |  |  |  |  | $ | 364,560 |  |  |  |  | $ | 2,525,213 |  |  |  |  | $ | 2,468,265 |  |
Equity Valuation Assumption Difference, Footnote | (8) The fair value of equity component of the CAP calculation was determined in accordance with SEC methodology for this disclosure. Unlike the SCT, which reflects the grant date fair value of equity awards granted during the applicable year, the CAP table reflects equity fair value as follows: • for awards granted during the applicable year (and which are still outstanding), the year-end value; plus • for awards granted during prior years that were still outstanding as of the applicable year-end, the change in value as of the applicable year-end compared against the prior year-end; plus • for awards granted in prior years that vested during the applicable year, the change in value as of the vesting date compared against the prior year-end; plus • for any awards granted in the applicable year that vested during the applicable year, the value as of the vesting date; plus • the value of any dividend equivalents that were paid during the applicable year that are not otherwise included in total compensation; minus • for awards granted in prior years that were forfeited during the applicable year, the value as of the prior year-end. The specific calculations with respect to the CAP fair value of equity for the relevant years are shown in the tables below:
First PEO – CAP Equity Adjustments |  | 2024 | 2023
YE Value of Current Year Awards Outstanding as of YE |  |  | $ | 2,057,295 |  |  |  | $ | 616,999 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  |  | $ | 240,247 |  |  |  | $ | (187,294 | ) |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  |  | $ | 5,571 |  |  |  | $ | (21,797 | ) |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  |  | $ | — |  |  |  | $ | — |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  |  | $ | — |  |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  |  | $ | — |  |  |  | $ | — |  |
Value of Equity for CAP Purposes |  |  | $ | 2,303,113 |  |  |  | $ | 407,908 |  |
Second PEO – CAP Equity Adjustments |  | 2022 |  | 2021 |  | 2020
YE Value of Current Year Awards Outstanding as of YE |  |  | $ | — |  |  |  |  | $ | 4,664,583 |  |  |  |  | $ | 3,000,006 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | — |  |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  |  | $ | (1,748,149 | ) |  |  |  | $ | 1,002,070 |  |  |  |  | $ | — |  |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  |  | $ | 1,133,119 |  |  |  |  | $ | — |  |  |  |  | $ | 1,999,992 |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  |  | $ | — |  |  |  |  | $ | — |  |  |  |  | $ | — |  |
Value of Equity for CAP Purposes |  |  | $ | (615,030 | ) |  |  |  | $ | 5,666,653 |  |  |  |  | $ | 4,999,998 |  |
Third PEO – CAP Equity Adjustments |  | 2020
YE Value of Current Year Awards Outstanding as of YE |  |  | $ | 5,583,464 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  |  | $ | (546,293 | ) |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  |  | $ | (1,613,931 | ) |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  |  | $ | — |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  |  | $ | — |  |
Value of Equity for CAP Purposes |  |  | $ | 3,423,240 |  |
Non-PEO NEOs – CAP Equity Adjustments | 2024 | 2023 | 2022 | 2021 | 2020
YE Value of Current Year Awards Outstanding as of YE |  | $ | 834,923 |  |  |  | $ | 560,818 |  |  |  | $ | 350,057 |  |  |  | $ | 1,310,553 |  |  |  | $ | 717,561 |  |
Change in Value as of YE for Prior Year Awards Outstanding as of YE |  | $ | 122,479 |  |  |  | $ | (150,476 | ) |  |  | $ | (496,890 | ) |  |  | $ | 60,423 |  |  |  | $ | (37,398 | ) |
Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year |  | $ | 2,366 |  |  |  | $ | (9,414 | ) |  |  | $ | (106,757 | ) |  |  | $ | 37,056 |  |  |  | $ | (499,755 | ) |
Value as of Vesting Date for Current Year Awards That Vested During the Year |  | $ | 288,498 |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | 1,254,596 |  |
Value as of Vesting Date for Dividend Equivalents Paid During the Year Not Otherwise Included in Total Compensation |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |
Value as of Prior YE for Prior Year Awards Forfeited During the Year |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |  |  | $ | — |  |
Value of Equity for CAP Purposes |  | $ | 1,248,266 |  |  |  | $ | 400,928 |  |  |  | $ | (253,590 | ) |  |  | $ | 1,408,032 |  |  |  | $ | 1,435,004 |  |
Compensation Actually Paid vs. Total Shareholder Return | The following chart shows the relationship of the compensation actually paid to our PEOs and the average compensation actually paid to our other non-PEO NEOs to the total shareholder return for the Company (“PDX”) and for the S&P 600 Healthcare Index (“S&P 600 HC”). |  |  |  |
Compensation Actually Paid vs. Company Selected Measure | The following chart shows the relationship of the compensation actually paid to our PEOs and the average compensation actually paid to our other non-PEO NEOs as compared to our net (loss) income and our Adjusted EBITDA (“AEBITDA”). |  |  |  |
Tabular List, Table | Tabular List of Most Important Financial Performance Measures We consider the below financial performance measures to be the most important measures used by us to link NEO compensation to Company performance. For further information regarding these performance metrics and their function in our executive compensation program, please see “Compensation Discussion and Analysis.”
Most Important Financial Measures
• Adjusted EBITDA | • Adjusted Income From Operations
• Stock Price |
Total Shareholder Return Amount | $ 47.21 | 33.47 | 53.47 | 97.91 | 88.31
Peer Group Total Shareholder Return Amount | 102.9 | 99.53 | 102.25 | 138.98 | 131.41
Net Income (Loss) | $ (99,069,000) | $ (60,408,000) | $ 66,331,000 | $ 130,937,000 | $ (796,488,000)
Company Selected Measure Amount | 224,022,000 | 200,418,000 | 241,033,000 | 265,476,000 | 219,872,000
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted EBITDA |  |  |  |
Non-GAAP Measure Description | Adjusted EBITDA is the financial measure from the Tabular List of 2024 Most Important Measures shown below, which, in the Company’s assessment, represents for 2024 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 32 and is a non-GAAP financial measure |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted Income From Operations |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Stock Price |  |  |  |
First PEO |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
PEO Total Compensation Amount | $ 3,301,012 | $ 2,237,839 |  |  |
PEO Actually Paid Compensation Amount | $ 4,424,038 | $ 1,620,732 |  |  |
PEO Name | Dr. Swift | Dr. Swift |  |  |
First PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (1,180,087) | $ (1,025,015) |  |  |
First PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 2,303,113 | 407,908 |  |  |
First PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 2,057,295 | 616,999 |  |  |
First PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 240,247 | (187,294) |  |  |
First PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 |  |  |
First PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 5,571 | (21,797) |  |  |
First PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 |  |  |
First PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 |  |  |
Second PEO |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
PEO Total Compensation Amount |  |  | $ 4,655,746 | $ 6,848,969 | $ 6,438,682
PEO Actually Paid Compensation Amount |  |  | $ 540,703 | $ 9,015,601 | $ 6,438,682
PEO Name |  |  | Mr. Ordan | Mr. Ordan | Mr. Ordan
Second PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | $ (3,500,013) | $ (3,500,021) | $ (4,999,998)
Second PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (615,030) | 5,666,653 | 4,999,998
Second PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 4,664,583 | 3,000,006
Second PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0
Second PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 1,133,119 | 0 | 1,999,992
Second PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (1,748,149) | 1,002,070 | 0
Second PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0
Third PEO |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
PEO Total Compensation Amount |  |  |  |  | 7,597,254
PEO Actually Paid Compensation Amount |  |  |  |  | $ 4,870,493
PEO Name |  |  |  |  | Dr. Medel
Third PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | $ (6,150,001)
Third PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | 3,423,240
Third PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | 5,583,464
Third PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | (546,293)
Third PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | 0
Third PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | (1,613,931)
Third PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | 0
Third PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  | 0
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (715,395) | (931,681) | (1,081,261) | (990,016) | (2,163,436)
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,248,266 | 400,928 | (253,590) | 1,408,032 | 1,435,004
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 834,923 | 560,818 | 350,057 | 1,310,553 | 717,561
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 122,479 | (150,476) | (496,890) | 60,423 | (37,398)
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 288,498 | 0 | 0 | 0 | 1,254,596
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 2,366 | (9,414) | (106,757) | 37,056 | (499,755)
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 0 | 0 | 0 | 0 | 0
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 0 | $ 0 | $ 0 | $ 0 | $ 0

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 4 + Details
Name: | ecd_EquityValuationAssumptionDifferenceFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=md_FirstPEOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=md_SecondPEOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=md_ThirdPEOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |